Lytix Biopharma Asa · OSL:LYTIX
Lytix Biopharma Asa — Q2 2023 Earnings Presentation
23 slides from Lytix Biopharma Asa's earnings presentation, Aug 31, 2023
Slide 1: Lytix Biopharma AS
Lytix Biopharma AS Building the Phase II evidence base First half and second quarter 2023 presentation August 31, 2023
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person
Slide 3: Presenting team
Presenting team Øystein Rekdal / CEO and co-founder • Dr. Rekdal’s post-doctoral research forms the basis of Lytix Biopharma’s oncolytic molecule platform. • Over the last years Rekdal has been instrumental in the development of intra-tumoral therapy of LTX-315 from preclinical to clinical ‘proof of
Slide 4: Scientifically and commercially validated
Scientifically and commercially validated Unique non-viral oncolytic platform Innovative pipeline that overcomes major with broad pipeline opportunities challenges in cancer therapy • Lead candidate; one completed and • Tumor heterogeneity two ongoing Phase II studies • Cold tumors • Promising resul
Slide 5: Highlights for the second quarter
Highlights for the second quarter - and post-period events Verrica Pharmaceuticals’ Phase II study evaluating LTX-315 for the treatment of basal cell carcinoma (BCC) Countries with active sites ‒ Complete clearance observed in four lesions, 95% clearance in one lesion and 30% clearance in one lesion
Slide 6: Clinical/Operational update
Clinical/Operational update
Slide 7: ATLAS-IT-05 - All 20 patients recruited
ATLAS-IT-05 - All 20 patients recruited On August 28th, 2023, Lytix announced that all 20 patients have been recruited to the study An abstract with interim results from the study has been approved for presentation at European Society for Medical Oncology (ESMO) Congress 2023, 20-24 October If inter
Slide 8: ATLAS-IT-06: NeoLIPA neoadjuvant study in melanoma
ATLAS-IT-06: - NeoLIPA: Neoadjuvant study with LTX-315 in melanoma patients Neoadjuvant LTX-315 in combination with pembrolizumab in resectable stage III/IV melanoma (NeoLIPA) Conducted by principal investigator senior physician PhD Henrik Jespersen at Oslo University Hospital, Radiumhospitalet Esti
Slide 9: Effect of pembrolizumab alone in a neoadjuvant melanoma study
Effect of pembrolizumab alone in a neoadjuvant melanoma study (SWOG 1801 clinical results) 9 of 142 patients (6%) had a complete response and 58 (41%) a partial response 28 of 132 patients (21%) had a complete pathological response (no viable tumor) Potential for combining pembrolizumab with LTX- 31
Slide 10: Verrica Pharmaceuticals - Phase II study in good progress
Verrica Pharmaceuticals - Phase II study in good progress Verrica reported promising interim Phase II data with LTX-315 (VP-315) at the 2023 AAD Innovation Meeting In the presentation, Dr. Neal Bhatia MD, Director of Clinical Dermatology Therapeutics Clinical Research in San Diego, stated: ‒ Subject
Slide 11: Basal cell carcinoma market in the US
Basal cell carcinoma market in the US BCC creates significant burden for the patient and healthcare system ‒ In the US, skin cancer accounts for $8.1 billion in total healthcare costs ‒ Non-melanoma skin cancer represents 59% of all skin cancers ‒ 3-4 million BCC incidences annually Treatment modali
Slide 12: Pipeline
Pipeline Product Description Indication Discovery Preclinical Phase I Phase II Phase III candidate ATLAS-IT-05 Melanoma patients Pembrolizumab progressed on (Keytruda®) checkpoint inhibitors Phase II by Verrica Pharmaceuticals Basal cell carcinoma (monotherapy) LTX-315 Neoadjuvant ATLAS-IT-06 resect
Slide 13: Key figures
Key figures
Slide 14: Key figures – profit and loss
Key figures – profit and loss Unaudited Unaudited Amounts in NOK thousands Q2 2023 Q2 2022 FY 2022 Total operating income 449 11,177 17,273 Total operating expenses (34,607) (20,418) (82,968) Loss from operations (34,159) (9,241) (65,695) Loss for the period (31,435) (433) (56,006) Due to the signif
Slide 15: Key figures - high level of activity
Key figures - high level of activity 40 000 30 000 Total operating expense Direct R&D expenses 25 000 30 000 20 000 20 000 15 000 10 000 10 000 5 000 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2023 2022 2023 2022 40 000 Operating expenses 22/23 Cash and short term financial investments 200 000 30 000 150 000 20 00
Slide 16: Key figures – balance sheet
Key figures – balance sheet Unaudited Unaudited Amounts in NOK thousands 30.06.2023 30.06.2022 31.12.2022 Assets Property, plant and equipment 144 132 124 Trade and other receivables 5,959 7,643 6,735 Short-term financial investments 41,961 - 50,606 Cash and cash equivalents 58,257 177,084 94,552 To
Slide 17: Outlook
Outlook
Slide 18: Key objectives moving forward
Key objectives moving forward LTX-315 MONOTHERAPY Clinical development Local treatment → Abscopal effect ‒ Analysis of interim results from ATLAS-IT-05 study for presentation at ESMO in October ‒ Continue to support Verrica Pharmaceuticals’ Phase II trial with LTX-315 in BCC ‒ Support and initiate t
Slide 19: Q&A
Q&A IR enquiries: [email protected]
Slide 20: Interim Financial Statements
Interim Financial Statements
Slide 21: Condensed Interim statement of profit and loss
Condensed Interim statement of profit and loss Unaudited Unaudited Amounts in NOK thousands Q2 2023 Q2 2022 FY 2022 Revenue 74 - 1,409 Other operating income 375 11,177 15,864 Total operating income 449 11,177 17,273 Payroll and related expenses (7,549) (6,175) (21,133) Depreciation and amortization
Slide 22: Condensed Interim statement of financial position
Condensed Interim statement of financial position Unaudited Unaudited Amounts in NOK thousands 30.06.2023 30.06.2022 31.12.2022 Assets Non-current assets Property, plant and equipment 144 132 124 Total non-current assets 144 132 124 Current assets Trade and other receivables 5,959 7,643 6,735 Short-
Slide 23: Condensed Interim statement of cash flows
Condensed Interim statement of cash flows Unaudited Unaudited Amounts in NOK thousands Q2 2023 Q2 2022 FY 2022 Cash flows from operating activities Loss for the period (31,435) (433) 56,006) Adjustments for: Depreciation of property, plant and equipment 14 6 30 Share-based payment expense 1,086 344